Relationship Between Polymorphism of Ghrelin Gene and the Change of Plasma Glucose During Risperidone Treatment in Schizophrenia Patients

亢万虎,郭丽阳,李强,吕社民,高成阁,杨小波,王崴

2009-01-01

Abstract:Objective To assess the change of fasting plasma glucose during risperidone treatment in patients with schizophrenia or schizophrenia-like psychosis and to analyze the relationship between the ghrelin gene Leu72Met polymorphism and the change of fasting plasma glucose.Methods Totally 66 patients with schizophrenia or schizophrenia-like psychosis were treated with risperidone for 10 weeks.Their fasting plasma glucose was measured at admission,and 4-week and 10-week treatment.The polymorphism of ghrelin gene was determined with PCR-RFLP.Results During risperidone treatment,fasting plasma glucose of the patients increased significantly at 4-week and 10-week [(4.994±0.808),(5.211±0.655)mmol/L vs.(4.589±0.832)mmol/L,F=13125.61,P0.05].The change of fasting plasma glucose did not differ significantly between the two sexes(F=0.147,P0.05),but it increased earlier in the females than in the males.There was a correlation between the change of fasting plasma glucose and the ghrelin gene Leu72Met polymorphism.The patients with Leu72 allele had a higher level of fasting plasma glucose [(0.702±0.009)mmol/L vs.(0.677±0.008) mmol/L,F=4.269,P0.05].Conclusion During the treatment of risperidone,patients with schizophrenia had increased fasting plasma glucose,which was more common in the females.The Leu72 allele in ghrelin gene may be a risk factor of the increase of fasting plasma glucose caused by risperidone treatment.